Search

Displaying results 3211 - 3220 of 10000 in total
  1. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    [A203255] Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and [tetracycline].[A19429,L13880]

    Synonyms: N-Lysinomethyltetracycline, (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide
  2. Target

    Cyclin-dependent kinase 9

    go.drugbank.com/bio_entities/BE0002207
    TargetHumans

    This complex is inactive when in the 7SK snRNP complex form (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed … The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351).

    Synonyms: Tat-associated kinase complex catalytic subunit
  3. Target

    Proteasome subunit beta type-5

    go.drugbank.com/bio_entities/BE0002348
    TargetHumans

    Within the 20S core complex, PSMB5 displays a chymotrypsin-like activity … Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins.

    Synonyms: Multicatalytic endopeptidase complex epsilon chain
  4. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

    Categories: Gene Products, env, env Gene Products, Human Immunodeficiency Virus
  5. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.

  6. Drug

    Valganciclovir

    go.drugbank.com/drugs/DB01610
    ApprovedInvestigational

    Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.

  7. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production … [L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life.

  8. Drug

    Arginine glutamate

    go.drugbank.com/drugs/DB13207
    Investigational

    Mixtures: NUTRIFLEX PLUS IN 1000ML TWIN FLEX, NUTRIFLEX PLUS IN 2000ML TWIN FLEX
  9. Drug

    Lithium citrate

    go.drugbank.com/drugs/DB14507
    ApprovedInvestigational

  10. Drug

    Kanamycin

    go.drugbank.com/drugs/DB01172
    ApprovedInvestigationalVet approvedWithdrawn

    Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.